Apellis Pharmaceuticals, Inc. (APLS)
25.01
+0.04
(+0.18%)
USD |
NASDAQ |
Dec 12, 15:39
Apellis Pharmaceuticals Research and Development Expense (Quarterly): 68.19M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Biogen, Inc. | 369.60M |
| Amicus Therapeutics, Inc. | 23.42M |
| Fortress Biotech, Inc. | 0.208M |
| Ultragenyx Pharmaceutical, Inc. | 207.61M |
| Fulcrum Therapeutics, Inc. | 14.00M |